| Liu, Zhigang |
| Recruiting | 3 | 315 | RoW | TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Stage III Non-small-cell Lung Cancer | 12/22 | 03/25 | | |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
NCT05780372: Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 474 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy | Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Chongqing University Cancer Hospital, Dongguan People's Hospital, LiuZhou People's Hospital | Nasopharyngeal Carcinoma, Radiotherapy; Complications | 05/25 | 05/28 | | |
| Recruiting | 2 | 150 | RoW | Anlotinib Hydrochloride, Placebo, Radiation Therapy, Temozolomide | Sun Yat-sen University | Glioblastoma | 10/23 | 10/23 | | |
NCT06301165: TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 162 | RoW | TPC induction chemotherapy, GP induction chemotherapy | Sun Yat-sen University | Nasopharyngeal Carcinoma | 12/24 | 12/28 | | |
NeoRTPC02, NCT05343325: The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC |
|
|
| Recruiting | 2 | 25 | RoW | Tislelizumab, Albumin-bound paclitaxel, Cisplatin, Low-dose radiotherapy | Fifth Affiliated Hospital, Sun Yat-Sen University, Dongguan People's Hospital | Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment | 03/24 | 03/27 | | |
NCT05290194: Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 28 | RoW | SBRT radiotherapy + Conventionally fractionated radiotherapy, PD-1 inhibitor, Immune Checkpoint Inhibitors, Capecitabine, Xeloda | Fifth Affiliated Hospital, Sun Yat-Sen University | Radiotherapy, PD-1 Inhibitor, Capecitabine, Nasopharyngeal Carcinoma | 12/26 | 01/27 | | |
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | T3011 high dose, T3011 middle dose, T3011 low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 12/25 | 05/26 | | |
NCT05842798: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults |
|
|
| Completed | 1 | 28 | RoW | TNM002, Placebo | Trinomab Biotech Co., Ltd. | Healthy Volunteers | 02/22 | 02/22 | | |
NeoTGP01, NCT04947241: Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC |
|
|
| Recruiting | 1 | 20 | RoW | PD-1 inhibitor+ Gemcitabine + Cisplatin, Toripalimab | Fifth Affiliated Hospital, Sun Yat-Sen University | Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy | 01/26 | 01/26 | | |
